Belantamab mafodotin approved!
#mmsm #oncopharm
@SagarLonialMD

PI @ bit.ly/39YwDI6.

Clin pharm: BCMA directed ADC with MMAF maytansinoid payload (less neurotox vs MMAE)

Dose=2.5 mg/kg over 30 mins Q3 wk with art. tears QID throughout rx (avoid contact lenses)

1/ REMS for ocular AEs (blurred vision - sx in 22%, Gr 3/4 in 4%, other exam findings).

No exposure-response relationship (thus dose = 2.5 rather than 3.4).

Positive exposure-tox relationship (e.g., corneal AEs)

2/